Publication: Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
New England Journal of Medicine (NEJM/MMS)
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Nishino, Mizuki, Lynette M. Sholl, Hiroto Hatabu, Nikhil H. Ramaiya, and F. Stephen Hodi. 2015. “Anti–PD-1–Related Pneumonitis During Cancer Immunotherapy.” New England Journal of Medicine 373 (3) (July 16): 288–290. doi:10.1056/nejmc1505197.
Research Data
Abstract
The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T-cell checkpoints, is a promising new therapy for advanced cancers.1 Recent trials have shown substantial clinical activity of anti–PD-1 antibodies in advanced cancers and led to the approvals of these agents, including pembrolizumab for melanoma and nivolumab for melanoma and squamous-cell lung cancer.2-4 Pneumonitis related to the use of antibodies against PD-1 is an immune-mediated toxic effect that resulted in three drug-related deaths in a phase 1 trial.1 Clinical identification and management of pneumonitis are contingent on radiographic assessment. We report three cases of pneumonitis associated with the use of anti–PD-1 antibodies in patients with melanoma.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service